Multicentric Phase 1 Study With Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine) or CPX-351 in Patients of 60 years old or more With adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)

2022-502585-25-00 Protocol RC22_0372 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 6 Feb 2025 · Status Ongoing, recruiting · 1 EU/EEA countries · 3 sites · Protocol RC22_0372

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 12
Countries 1
Sites 3

Adult patients with adverse Risk Acute Myeloblastic Leukemia

Key facts

Sponsor
Centre Hospitalier Universitaire De Nantes
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Hemic and Lymphatic Diseases [C15]
Trial duration
6 Feb 2025 → ongoing
Decision date (initial)
2023-02-07
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Adult patients with adverse Risk Acute Myeloblastic Leukemia

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Centre Hospitalier Universitaire De Nantes

Sponsor organisation
Centre Hospitalier Universitaire De Nantes
Address
1 Place Alexis Ricordeau
City
Nantes
Postcode
44000
Country
France

Scientific contact point

Organisation
Centre Hospitalier Universitaire De Nantes
Contact name
Pierre PETERLIN

Public contact point

Organisation
Centre Hospitalier Universitaire De Nantes
Contact name
Pierre PETERLIN

Locations

1 EU/EEA country · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruiting 12 3
Rest of world 0

Investigational sites

France

3 sites · Ongoing, recruiting
Centre Hospitalier Universitaire De Rennes
Service d'hématologie clinique, 2 Rue Henri Le Guilloux, 35000, Rennes
Centre Hospitalier Universitaire De Nantes
service d'hématologie clinique, 1 Place Alexis Ricordeau, 44000, Nantes
Centre Hospitalier Universitaire D Angers
Service d'hématologie clinique, 4 Rue Larrey, 49933, Angers Cedex 9

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2025-02-06 2025-02-06

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2022-11-16 France Acceptable
2023-02-07
2023-02-07
2 SUBSTANTIAL MODIFICATION SM-1 2023-04-17 France Acceptable
2023-05-26
2023-05-30
3 SUBSTANTIAL MODIFICATION SM-2 2024-07-09 France Acceptable
2024-07-30
2024-07-30
4 SUBSTANTIAL MODIFICATION SM-3 2025-01-21 France Acceptable
2025-02-12
2025-02-19